NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Clinical Trials
559 trialsNCT04609566 2026-03-16
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
Phase 2 Completed
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05923060 2026-02-20
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02517736 2026-02-17
O-Mel-Sora
University Hospital, Caen
Phase 2 Completed
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT05872854 2026-02-09
RW-HPN-MF-01
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT05419388 2026-02-04
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT02636569 2026-01-21
Topical Chemoprevention of Skin Cancer Biomarkers
University of Alabama at Birmingham
Phase 2 Completed
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04526899 2026-01-08
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
BioNTech SE
Phase 2 Completed
NCT03405155 2025-12-31
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
Thomas Jefferson University
Phase 2 Completed
NCT04154943 2025-12-23
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Completed
NCT01319565 2025-12-19
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
NCT01950390 2025-12-11
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02360579 2025-12-09
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Completed
NCT04570332 2025-11-26
SPOTLIGHT203
Highlight Therapeutics
Phase 2 Completed
NCT04796194 2025-11-20
ATLAS-IT-05
Lytix Biopharma AS
Phase 2 Completed
NCT01473004 2025-11-14
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Thomas Jefferson University
Phase 2 Completed
NCT02576431 2025-11-12
NAVIGATE
Bayer
Phase 2 Completed
NCT00244816 2025-10-23
Taxoprexin® Treatment for Advanced Eye Melanoma
American Regent, Inc.
Phase 2 Completed
NCT06027619 2025-10-23
Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00249262 2025-09-26
Taxoprexin Treatment for Advanced Skin Melanoma
American Regent, Inc.
Phase 2 Completed
NCT04988841 2025-08-28
PICASSO
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT03599713 2025-08-05
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
Phase 2 Completed
NCT03409432 2025-07-25
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02553642 2025-07-22
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT06319794 2025-07-18
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
TORQUR
Phase 2 Completed
NCT01378975 2025-06-25
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT05188729 2025-06-18
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03618641 2025-05-14
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
University of Pittsburgh
Phase 2 Completed
NCT05542342 2025-05-14
SITISVEAL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03472586 2025-04-24
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Thomas Jefferson University
Phase 2 Completed
NCT04552990 2025-04-23
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01355120 2025-04-09
DeCOG
University Hospital, Essen
Phase 2 Completed
NCT02196961 2025-04-09
ADMEC-O
University Hospital, Essen
Phase 2 Completed
NCT02523313 2025-04-09
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
University Hospital, Essen
Phase 2 Completed
NCT02902029 2025-04-09
ImmunoCobiVem
University Hospital, Essen
Phase 2 Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT01998984 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 2 Completed
NCT02305888 2025-03-10
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
LEO Pharma
Phase 2 Completed
NCT05061017 2025-03-07
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
University of Pittsburgh
Phase 2 Completed
NCT04417530 2025-03-03
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Aura Biosciences
Phase 2 Completed